Timely reauthorization of PDUFA and BsUFA is vital to the FDA ’s review of medicines

As we ’ve discussed on this blog before, timely reauthorization of thePrescription Drug User Fee Act (PDUFA) and theBiosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug Administration ’s (FDA) ability to keep pace with the number of innovative drugs, biologics and biosimilars entering the regulatory review pipeline.
Source: The Catalyst - Category: Pharmaceuticals Tags: PDUFA Biologics and Biosimilars Source Type: news